Uso de Molnupiravir en el tratamiento de Covid 19 en adultos desde enero 2020 hasta abril 2022

Abstract

COVID-19 disease has not been fully controlled. Although great benefits have been achieved in COVID 19 research and many of the antiviral drugs used have shown good therapeutic effects against this disease, easily distributed oral antiviral drugs are still needed to treat this disease, such as molnupiravir, which is a new drug. safe and very well tolerated at therapeutic doses, since after having used it for 5 days in oral therapy, satisfactory results were obtained with this medication. Materials and Methods: For the preparation of this article, several highly relevant data sources were taken into account, such as: PubMed, The Cochrane, Medline, IntraMed, SciELO, WHO, UpToDate, etc. and journals with proven scientific evidence since January 2020. until April 2022, in English and Spanish. Results: Through analyzes carried out as well as through the results obtained by the different bibliographic reviews, it has been possible to determine that molnupiravir is a new oral antiviral agent under development for the treatment of COVID-19, a study was reviewed that has been able to demonstrate that Molnupiravir improves the replication of viral RNA mutations, through data collection it was possible to observe that in an article in which a study was carried out with 2440 patients with Covid 19 the result was significant since the range of mortality or hospitalizations was 0.22 reaching a 95% CI for patients with COVID 19 in the drug group. But at the same time making it known that this medicine will only be used in mild to moderate COVID 19 since in severe cases more studies are still needed to be able to use it. Conclusion: The information collected on the benefit of the use of Molnupiravir in the treatment of patients with COVD-19 disease, establishes that molnupiravir is the first oral antiviral drug that demonstrates a significant benefit in reducing hospitalization or death in mild cases of COVID. -19 with a 95% CI on items used, which means it could be an important weapon in the battle against SARSCoV-2